Funds will support extending their Resonance Sonomanometry™ technology for children.
IRVINE, Calif., July 21, 2025 /PRNewswire/ — Esperto Medical™, Inc. a healthtech startup specializing in critical care and remote patient monitoring, has been awarded a grant by the Midwest Pediatric Device Consortium (MPDC) to extend their noninvasive continuous vital sign monitoring technology for use in pediatric patients.
Cofounder and Chief Medical Officer, Alaina Rajagopal, MD, PhD explained, “Esperto is committed to making its technology accessible to all patients, regardless of age, size, skin color, location, or health status. Children often don’t have access to the same sorts of technologies as adults because development takes longer, their body size is more variable, and safety for our most vulnerable patients is often a serious concern.”
The funds will support development and clinical testing of a noninvasive vital sign monitor for children based on Esperto’s new Resonance Sonomanometry™ (RSM) technology. RSM uses sound waves at different frequencies to directly measure blood pressure within arteries, avoiding the variability of other approaches – and requires no calibration, making it easy to set up and use. Details of the technique are published in PNAS Nexus.
The MPDC is a branch of the national Pediatric Device Consortium (PDC) Program funded and organized by the FDA’s Office of Orphan Products Development (OOPD). Since 2009, the PDC program has provided a venue for advising, funding, and accelerating pediatric medical device technologies towards market availability and clinical use. The PDC program aims to reduce this gap so that every patient, regardless of age or size, has access to state-of-the-art technology.
“We believe that better technology will lead to better access and, ultimately, better care,” said Aditya Rajagopal, PhD, cofounder and CEO of Esperto Medical. “We are thrilled to have the chance to bring forward a solution to a longstanding clinical problem in pediatric critical care: accurate, noninvasive, calibration-free, continuous blood pressure monitoring.”
About Esperto Medical™
Named Octane’s Best Emerging Disruptor of 2024, Esperto is dedicated to delivering the future of healthcare and expanding access by creating revolutionary noninvasive diagnostic technologies. Medicine is ready for huge breakthroughs, yet the burden of some essential tasks, like vital sign monitoring, hinders efficiency. Esperto aims to free clinicians and patients from the limitations of outdated technology. Learn more at www.esperto.health.
SOURCE Esperto Medical
